{"id":"icodextrin-peritoneal-dialysis-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Peritonitis"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Hyperamylasemia"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL1201472","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Icodextrin functions as a colloid osmotic agent with a high molecular weight that cannot easily cross the peritoneal membrane, creating an osmotic gradient that drives ultrafiltration of excess fluid during peritoneal dialysis. Unlike glucose-based dialysates, icodextrin provides sustained ultrafiltration over longer dwell times and reduces glucose absorption, making it particularly useful for overnight or long-dwell exchanges in peritoneal dialysis patients.","oneSentence":"Icodextrin is a glucose polymer that acts as an osmotic agent in peritoneal dialysis solution to draw excess fluid from the blood across the peritoneal membrane.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:57.401Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peritoneal dialysis in end-stage renal disease patients requiring fluid removal"}]},"trialDetails":[{"nctId":"NCT03994471","phase":"PHASE3","title":"Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.","status":"RECRUITING","sponsor":"Iperboreal Pharma Srl","startDate":"2022-12-14","conditions":"End Stage Renal Disease","enrollment":170},{"nctId":"NCT06492031","phase":"","title":"Observational Study of the Use of Extraneal in Peritoneal Dialysis in Patients","status":"RECRUITING","sponsor":"Vantive Health LLC","startDate":"2024-06-28","conditions":"Chronic Renal Failure","enrollment":889},{"nctId":"NCT00397358","phase":"PHASE4","title":"Effect of Extraneal (Icodextrin)on Triglyceride Levels in PD Patients","status":"WITHDRAWN","sponsor":"Vantive Health LLC","startDate":"2006-11","conditions":"Peritoneal Dialysis, Hypertriglyceridemia","enrollment":""},{"nctId":"NCT04086212","phase":"PHASE2","title":"Ultrafiltration Efficacy of a PD Solution Containing Icodextrin-Xylitol-Carnitine","status":"WITHDRAWN","sponsor":"Iperboreal Pharma Srl","startDate":"2019-10-02","conditions":"End Stage Renal Disease (ESRD)","enrollment":""},{"nctId":"NCT06552546","phase":"NA","title":"Pharmacokinetics of Single- and Double-dose Icodextrin","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-08-15","conditions":"Peritoneal Dialysis","enrollment":16},{"nctId":"NCT05721404","phase":"PHASE4","title":"Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-05-24","conditions":"Peritoneal Dialysis","enrollment":194},{"nctId":"NCT05185999","phase":"PHASE1","title":"Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2022-10-17","conditions":"Chronic Kidney Failure","enrollment":10},{"nctId":"NCT06119373","phase":"NA","title":"Incremental PD With Single Icodextrin Exchange","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-12-01","conditions":"Peritoneal Dialysis Complication, Residual Kidney Function, Survival","enrollment":72},{"nctId":"NCT05943470","phase":"PHASE4","title":"The Difference Between Daily and Alternative Day Use of Icodextrin","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2023-08-01","conditions":"Peritoneal Dialysis Solution Adverse Reaction","enrollment":74},{"nctId":"NCT05780086","phase":"PHASE1","title":"Safety of and Tolerability to a Sodium-free Peritoneal Dialysis Solution","status":"UNKNOWN","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2023-02-03","conditions":"Chronic Kidney Diseases","enrollment":10},{"nctId":"NCT04001036","phase":"PHASE2","title":"Efficacy and Safety Assessments of a Peritoneal Dialysis Solution Containing Glucose, Xylitol, and L-Carnitine in CAPD","status":"TERMINATED","sponsor":"Iperboreal Pharma Srl","startDate":"2019-09-01","conditions":"End Stage Renal Disease","enrollment":11},{"nctId":"NCT03685747","phase":"PHASE1","title":"Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2018-11-15","conditions":"Peritoneal Dialysis-associated Peritonitis","enrollment":4},{"nctId":"NCT01228279","phase":"PHASE4","title":"Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2007-07","conditions":"End-stage Renal Disease (ESRD), Kidney Disease","enrollment":50},{"nctId":"NCT02708407","phase":"NA","title":"PD-HF: A Trial of Peritoneal Dialysis in Patients With Severe Heart Failure and Chronic Kidney Disease","status":"TERMINATED","sponsor":"University of Nottingham","startDate":"2016-01","conditions":"Heart Failure, Chronic Kidney Disease","enrollment":11},{"nctId":"NCT02212327","phase":"","title":"Testing Tissue Sodium Stores in CAPD Patients-Aims 1 & 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2014-08","conditions":"End Stage Renal Disease","enrollment":41},{"nctId":"NCT00755456","phase":"PHASE2","title":"Effect of an L-carnitine-containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)","status":"COMPLETED","sponsor":"Iperboreal Pharma Srl","startDate":"2008-01","conditions":"End Stage Renal Disease, Insulin Resistance","enrollment":35},{"nctId":"NCT00755404","phase":"PHASE2","title":"Effect of an L-Carnitine-Containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Diabetic Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)","status":"WITHDRAWN","sponsor":"Iperboreal Pharma Srl","startDate":"2007-06","conditions":"End Stage Renal Disease, Diabetes","enrollment":""},{"nctId":"NCT01758627","phase":"NA","title":"The Role of Peritoneal Dialysis in Patients With Refractory Heart Failure and Chronic Kidney Disease","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2013-12","conditions":"Refractory Heart Failure, Chronic Kidney Disease","enrollment":7},{"nctId":"NCT01242904","phase":"PHASE2","title":"Use of a Bimodal Solution for Peritoneal Dialysis","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2010-09-30","conditions":"End Stage Renal Disease","enrollment":36},{"nctId":"NCT01659554","phase":"PHASE2","title":"A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers","status":"TERMINATED","sponsor":"Columbia University","startDate":"2012-03","conditions":"Recurrent Ovarian Cancer, Fallopian Tube Cancer","enrollment":4},{"nctId":"NCT01119196","phase":"NA","title":"The Measurement of Insulin Resistance in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2010-09","conditions":"End Stage Renal Disease","enrollment":10},{"nctId":"NCT01044446","phase":"PHASE4","title":"Effect of Icodextrin on the Treatment Outcome of Peritoneal Dialysis Patients During Acute Peritonitis","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2010-01","conditions":"Peritonitis","enrollment":56},{"nctId":"NCT01170858","phase":"NA","title":"Effect of Icodextrin Solution on Preservation of Residual Renal Function in Patients on Peritoneal Dialysis","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-08","conditions":"End Stage Renal Disease","enrollment":100},{"nctId":"NCT01021878","phase":"PHASE4","title":"Study to Evaluate the Effects Icodextrin Versus Dianeal on Insulin Resistance in Nondiabetic Automated Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"Pontifícia Universidade Católica do Paraná","startDate":"2009-10","conditions":"Disorders Associated With Peritoneal Dialysis","enrollment":60},{"nctId":"NCT00369096","phase":"PHASE2","title":"Efficacy Study of the Addition of Bemiparin to Icodextrin Solution in Peritoneal Dialysis Patients (Bemidextrina)","status":"COMPLETED","sponsor":"Fundación Renal Iñigo Alvarez De Toledo","startDate":"2006-09","conditions":"Peritoneal Diseases","enrollment":76},{"nctId":"NCT00119990","phase":"NA","title":"Changes in Cardiovascular Hemodynamics During Peritoneal Dialysis","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2006-01","conditions":"Peritoneal Dialysis","enrollment":15},{"nctId":"NCT00725517","phase":"PHASE4","title":"Efficacy and Safety of a 7.5% Icodextrin Peritoneal Dialysis Solution in Once-Daily Long Dwell Exchange","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2005-12","conditions":"Chronic Kidney Disease, Peritoneal Dialysis","enrollment":2}],"_emaApprovals":[],"_faersSignals":[{"count":94,"reaction":"DEATH"},{"count":7,"reaction":"INFECTION"},{"count":4,"reaction":"CARDIAC DISORDER"},{"count":4,"reaction":"MALAISE"},{"count":3,"reaction":"MYOCARDIAL INFARCTION"},{"count":2,"reaction":"BLOOD GLUCOSE DECREASED"},{"count":2,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":2,"reaction":"DEHYDRATION"},{"count":2,"reaction":"FUNGAL PERITONITIS"},{"count":2,"reaction":"LUNG INFECTION"}],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Extraneal"],"phase":"marketed","status":"active","brandName":"Icodextrin Peritoneal Dialysis Solution","genericName":"Icodextrin Peritoneal Dialysis Solution","companyName":"RenJi Hospital","companyId":"renji-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Icodextrin is a glucose polymer that acts as an osmotic agent in peritoneal dialysis solution to enhance ultrafiltration and remove excess fluid from the peritoneal cavity. Used for Peritoneal dialysis in patients with end-stage renal disease requiring enhanced ultrafiltration.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}